Bristol-Myers Squibb signs agreements with Icon, Parexel
Pharmaceutical giant will expand its clinical studies capability with the new partners.
Bristol-Myers Squibb has signed agreements with clinical development service providers, Icon and Parexel, for joint strategic, operational and capability support of its clinical development program.
As per the agreement terms, Icon and Parexel are expected to provide support for Bristol-Myers Squibb's clinical studies to support its full development pipeline over the next three years.
Bristol-Myers Squibb is preparing for a large volume of clinical development work that is expected to require expanding upon its existing partnering approach for clinical development.
Brian Daniels, senior vice president of global development at Bristol-Myers Squibb, said: "These partnerships are expected to increase the operational capability of our clinical development organisation, and support our position in productivity and innovation.
"Working with Icon and Parexel, Bristol-Myers Squibb will enhance support for our pipeline and improve our ability to deliver medicines to patients with serious disease."
John Hubbard, president of clinical research services at Icon Group, said: ''We are delighted that Bristol-Myers Squibb has selected us to support its clinical development programs.
"Over the last ten years, we have forged a partnership by working hard to fully understand Bristol-Myers Squibb's requirements. We look forward to moving this partnership to another level and continuing to support Bristol-Myers Squibb's goal of bringing treatments to patients."
Josef von Rickenbach, chairman and CEO of Parexel, said: "We look forward to a deeply collaborative relationship with Bristol-Myers Squibb to help provide solutions for its growing pipeline, as well as leverage our capabilities and technology infrastructure to support the effectiveness of its clinical development programs."